RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Myelodysplastic Syndrome: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Biopsy-free score for screening myelodysplastic syndrome and related diseases in cytopenic patients
Sirilak Sutthinont et al., Scientific Reports (17 October 2026)
https://doi.org/10.1038/s41598-026-76612-8
- 2.
ASSESSMENT OF QUALITY OF LIFE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA
Halyna S. Starodub et al., Clinical and Preventive Medicine (17 October 2026)
https://doi.org/10.31612/2616-4868.7.2026.13
- 3.
As2S2 restores erythroid maturation in sf3b1-deficient zebrafish by upregulating smad7
Fan Wu et al., Annals of Hematology (16 October 2026)
https://doi.org/10.1007/s00277-026-07324-2
- 4.
A nutrition–inflammation index weighted toward disease burden: the lactate dehydrogenase-to-albumin ratio in TP53-mutated myeloid neoplasms
Xiaoqin Xin et al., Frontiers in Nutrition (16 October 2026)
https://doi.org/10.3389/fnut.2026.1966874
- 5.
Venetoclax-based combinations in high-risk myelodysplastic syndromes: highlights from ASH 2025 & EHA 2026.
Zugasti Ines et al., Experimental hematology & oncology (16 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42888461/
Clinical Trials : Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
NCT07422480 · Recruiting · Phase 3 · Takeda
Ages 18 and over
https://clinicaltrials.gov/study/NCT07422480
- 2.
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT06499285 · Recruiting · Phase 3 · Takeda
Ages 18 and over
https://clinicaltrials.gov/study/NCT06499285
- 3.
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
NCT06641414 · Recruiting · Phase 3 · Ascentage Pharma Group Inc.
Ages 18 and over
https://clinicaltrials.gov/study/NCT06641414
- 4.
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
NCT06656494 · Recruiting · Phase 1 · Beijing InnoCare Pharma Tech Co., Ltd.
Ages 18 and over
https://clinicaltrials.gov/study/NCT06656494
- 5.
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
NCT06465953 · Recruiting · Phase 3 · Institut de Recherches Internationales Servier
Ages 18 and over
https://clinicaltrials.gov/study/NCT06465953
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Myelodysplastic Syndrome
Myelodysplastic Syndrome encompasses a group of blood cancers in which the bone marrow produces abnormal, dysfunctional blood cells. The condition predominantly affects older adults and can progress to acute myeloid leukaemia. Treatment ranges from supportive care and growth factors to stem cell transplantation in eligible patients.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Myelodysplastic syndromes (MDS) often present with cytopenia, requiring bone marrow exams for diagnosis, which can be subjective and challenging. This study aimed to develop a non-invasive tool integrating clinical, laboratory, and genetic data to estimate MDS probability in Asian patients with unexplained cytopenia. Data were collected from three University hospitals in Thailand (2018–2023). Participants were adults with unexplained cytopenia. Next Generation Sequencing targeted a 40-gene myeloid panel. The predictive model was validated using bootstrapping. The study enrolled 285 participants, including 210 diagnosed with MDS (MDS: 144, MDS/MPN: 32, AML-MR: 34) and 75 non-MDS controls. The MDS group exhibited more severe anemia (Hb 8.7 vs. 10.2 g/dL; p < 0.001) and lower neutrophil count (1.8 vs. 1.9 × 109/L; p = 0.02) compared to non-MDS. Higher red cell distribution width (RDW ≥ 15%) and ≥ 2 mutations were more common in MDS (75% vs. 44% and 46% vs. 2.7%; p < 0.001). The most common gene mutations were TET2 (20.0%) , SRSF2 (16.7%) , ASXL1 (15.2%) , RUNX1 (11.9%) , and DNMT3A (10.5%) . A univariate analysis showed that Hb < 10 g/dL, ANC<1 × 109/L, platelet<100 × 109/L, RDW ≥ 15%, ≥ 2 mutations, one of six gene mutations ( TET2 , ASXL1 , SRSF2 , RUNX1 , TP53 , SF3B1 ), high-risk mutations ( NRAS , NPM1 , IDH2 , SETBP1 , CEBPA , JAK2 , IDH1 , FLT3 , KRAS ), and other risk mutations ( BCOR , U2AF1 , STAG2 , ZRSR2 , PTPN11 ) were significant predictors. The model containing 13 factors demonstrated an ROC curve area of 0.86. At a probability score of ≥ 45%, sensitivity, specificity, positive predictive value (PPV), and positive likelihood ratio (LR+) for MDS were 90.5%, 42.7%, 81.5%, and 1.6, respectively. A web-based calculator is available at ( https://tsh.or.th/mds/calculator/ ). A biopsy-free score integrating complete blood counts and gene mutations may help predict the probability of MDS and related diseases in patients with cytopenia. At a predicted probability of ≥ 45%, the score may help prioritize patients for further diagnostic evaluation, including bone marrow examination.
Common Questions
What is Myelodysplastic Syndrome?
Myelodysplastic Syndrome encompasses a group of blood cancers in which the bone marrow produces abnormal, dysfunctional blood cells. The condition predominantly affects older adults and can progress to acute myeloid leukaemia. Treatment ranges from supportive care and growth factors to stem cell transplantation in eligible patients.
How many clinical trials are available for Myelodysplastic Syndrome?
RareWays currently indexes 1988 clinical trials for Myelodysplastic Syndrome, of which 236 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Myelodysplastic Syndrome come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Myelodysplastic Syndrome.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.